Medication Guide App

Generic Evista Availability

Evista is a brand name of raloxifene, approved by the FDA in the following formulation(s):

EVISTA (raloxifene hydrochloride - tablet;oral)

  • Manufacturer: LILLY
    Approval date: December 9, 1997
    Strength(s): 60MG [RLD] [AB]

Has a generic version of Evista been approved?

A generic version of Evista has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Evista and have been approved by the FDA:

raloxifene hydrochloride tablet;oral

  • Manufacturer: TEVA PHARMS USA
    Approval date: March 4, 2014
    Strength(s): 60MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Evista. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Methods of use for inhibiting bone loss and lowering serum cholesterol
    Patent 5,478,847
    Issued: December 26, 1995
    Inventor(s): Draper; Michael W.
    Assignee(s): Eli Lilly and Company
    A method of inhibiting bone loss or resorption, or lowering serum cholesterol, comprising administering to a human in need thereof a compound having the formula ##STR1## or a pharmaceutically acceptable salt or solvate thereof, in a low dosage amount. Also encompased by the invention is a a pharmaceutical formulation in unit dosage form comprising, per unit dosage, a low dosage amount.
    Patent expiration dates:
    • March 2, 2014
      ✓ 
      Patent use: USE FOR INHIBITING BONE RESORPTION
      ✓ 
      Sponsor has requested patent be delisted
  • Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
    Patent 5,811,120
    Issued: September 22, 1998
    Inventor(s): Gibson; Lowell L. & Hartauer; Kerry J. & Stowers; Julian L. & Sweetana; Stephanie A. & Thakkar; Arvind L.
    Assignee(s): Eli Lilly and Company
    This invention provides solid orally administerable pharmaceutical formulations comprising raloxifene hydrochloride, a surfactant being sorbitan fatty acid ester or a polyoxyethylene sorbitan fatty acid ester, polyvinylpyrrolidone, and a water soluble diluent which is polyol or sugar.
    Patent expiration dates:
    • March 2, 2014
  • Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
    Patent 5,972,383
    Issued: October 26, 1999
    Inventor(s): Gibson; Lowell L. & Hartauer; Kerry J. & Stowers; Julian L. & Sweetana; Stephanie A. & Thakkar; Arvind L.
    Assignee(s): Eli Lilly and Company
    This invention provides orally administerable pharmaceutical formulations comprising raloxifene, its ethers or esters, or a pharmaceutically-acceptable salt thereof, in combination with a hydrophilic carrier composition.
    Patent expiration dates:
    • March 2, 2014
      ✓ 
      Patent use: TREATMENT OR PREVENTION OF OSTEOPOROSIS
  • Benzothiophenes formulations containing same and methods
    Patent 6,458,811
    Issued: October 1, 2002
    Inventor(s): Gordon Nelson; Arbuthnot & Brian Weston; Dalder & Kerry John; Hartauer & Wayne Douglas; Luke & Robert Eugene; Stratford, Jr.
    Assignee(s): Eli Lilly and Company
    This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.
    Patent expiration dates:
    • March 10, 2017
      ✓ 
      Patent use: USE FOR PREVENTION OF BREAST CANCER
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Benzothiophenes, formulations containing same, and methods
    Patent 6,797,719
    Issued: September 28, 2004
    Inventor(s): Gordon Nelson; Arbuthnot & Brian Weston; Dalder & Kerry John; Hartauer & Wayne Douglas; Luke & Robert Eugene; Stratford, Jr.
    Assignee(s): Eli Lilly and Company
    This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.
    Patent expiration dates:
    • March 10, 2017
      ✓ 
      Drug product
  • Benzothiophenes, formulations containing same, and methods
    Patent 6,894,064
    Issued: May 17, 2005
    Inventor(s): Arbuthnot; Gordon Nelson & Dalder; Brian Weston & Hartauer; Kerry John & Luke; Wayne Douglas & Stratford, Jr.; Robert Eugene
    Assignee(s): Eli Lilly and Company
    This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.
    Patent expiration dates:
    • March 10, 2017
      ✓ 
      Patent use: PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
      ✓ 
      Drug product
  • Benzothiophenes, formulations containing same, and methods
    Patent 8,030,330
    Issued: October 4, 2011
    Inventor(s): Arbuthnot; Gordon Nelson & Dalder; Brian Weston & Hartauer; Kerry John & Luke; Wayne Douglas & Stratford, Jr.; Robert Eugene
    Assignee(s): Eli Lilly and Company
    This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.
    Patent expiration dates:
    • March 10, 2017
      ✓ 
      Drug product
  • Methods of use for inhibiting bone loss and lowering serum cholesterol
    Patent RE39050
    Issued: March 28, 2006
    Inventor(s): Draper; Michael W. & Black; Larry J.
    Assignee(s): Eli Lilly and Company
    A method of inhibiting bone loss or resorption, or lowering serum cholesterol, comprising administering to a human in need thereof a compound having the formula or a pharmaceutically acceptable salt or solvate thereof, in a low dosage amount. Also encompassed by the invention is a a pharmaceutical formulation in unit dosage form comprising, per unit dosage, a low dosage amount.
    Patent expiration dates:
    • March 2, 2014
      ✓ 
      Patent use: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
    • March 2, 2014
      ✓ 
      Patent use: PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • September 13, 2014 - ORPHAN DRUG EXCLUSIVITY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide
(web4)